Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Ethylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[3-difluoromethyl-4-phosphoanilinamidosuccinic Acid] Diamide (AC200)
Cat.#: ASSD-200
Specifications
Description Ethylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[3-difluoromethyl-4-phosphoanilinamidosuccinic Acid] Diamide, a water-soluble fluorescent-labeled probe, is used for labeling protein tyrosine phosphatases and other phosphatases. Size 500 μg Molecule Weight 1032.12 Molecular formula C44H53F2KN5O13PS2 Solubility Soluble in DMF, DMSO, Methanol and Water Storage Store at -20° C Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-192 4-Fluoro-7-nitrobenzofurazan (AC192) 5 mg, 25 mg, 50 mg inquiry ASSD-228 ImmunoHistoMount (AC228) 30 ml inquiry ASSD-199 4,7-Dioxaoctylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[2-fluoro-4′-phosphophenylacetic Acid] Diamide (AC199) 500 μg inquiry ASSD-189 7-Hydroxycoumarin-3-carboxylic acid (AC189) 100 mg inquiry ASSD-184 BTA-1 (AC184) 10 mg inquiry ASSD-205 Acridinium C2 NHS Ester (AC205) 5 mg, 10 mg inquiry ASSD-172 Ionomycin free acid (AC172) 1mg, 5mg inquiry ASSD-138 A3AR covalent antagonist (AC138) 50 μg inquiry ASSD-175 5-Carboxyfluorescein-N-hydroxysuccinimide Ester (AC175) 25 mg inquiry ASSD-107 Modified Mayer's Hematoxylin (AC107) 125 mL, 250 mL, 2×250mL inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket